Company Profile
Charles River Stock Price, News & Analysis
- Ticker:
- CRL
- Exchange:
- NYSE
- Sector:
- Biopharma
- Location:
- United States
Stock performance
265.51 USD (+1.84%)
Close
Last updated: August 6, 2026
8.42B USD
Market cap
Why the stock is moving
Following the latest company update, “Charles River Laboratories Announces Second-Quarter 2026 Results”, CRL closed up 11.4% at $260.72 on Aug 5, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Preclinical Research Services
Charles River Laboratories provides products and outsourced services used by pharmaceutical, biotechnology, academic and government researchers across early drug development.
Research Models and Services
The company supplies research models and related services used in basic research, target validation and preclinical studies. It also provides safety-assessment and discovery services.
Manufacturing Solutions
Charles River supports biologic testing, microbial solutions and other quality-control activities used in pharmaceutical manufacturing. Following divestitures, the company is refocusing on its core research and preclinical portfolio.
Future catalysts
Charles River’s catalysts are discovery-spend recovery, model-and-services demand, and any improvement in biopharma outsourcing. This matters because it helps show whether the company can turn its current footprint into a cleaner earnings profile. Better execution here can matter even before a new product or trial headline lands.
Recent news
- 01
Charles River Laboratories Announces Second-Quarter 2026 Results
Source: Charles River
- 02
- 03
- 04
- 05
Charles River Laboratories to Present at William Blair and Jefferies Conferences
Source: Charles River
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Charles River (CRL)?
Charles River (CRL) most recently closed at 265.51 USD, a +1.84% move versus the previous session.
What is the market cap of Charles River (CRL)?
Charles River currently has a market capitalization of 8.42B USD on BioPharmSignal.
What does Charles River do?
Preclinical Research Services Charles River Laboratories provides products and outsourced services used by pharmaceutical, biotechnology, academic and government researchers across early drug development. Research Models and Services The company supplies research models and related services used in basic research, target validation and preclinical studies....
On which exchange is CRL stock listed?
Charles River (CRL) is associated with NYSE, United States, Biopharma.
What is Preclinical?
Preclinical Research Services Charles River Laboratories provides products and outsourced services used by pharmaceutical, biotechnology, academic and government researchers across early drug development.
Which conditions is Charles River targeting with Preclinical?
Preclinical Research Services Charles River Laboratories provides products and outsourced services used by pharmaceutical, biotechnology, academic and government researchers across early drug development. Research Models and Services The company supplies research models and related services used in basic research, target validation and preclinical studies....
How does Charles River describe recent progress with Preclinical?
Charles River’s catalysts are discovery-spend recovery, model-and-services demand, and any improvement in biopharma outsourcing. This matters because it helps show whether the company can turn its current footprint into a cleaner earnings profile. Better execution here can matter even before a new product or trial headline lands.
What is Research?
Preclinical Research Services Charles River Laboratories provides products and outsourced services used by pharmaceutical, biotechnology, academic and government researchers across early drug development.